- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Monkeypox virus
- Pharmacological intervention
- Antivirals
- Tecovirimat
Intervention: Pharmacological intervention
This refers to the drug, therapy, or factor being studied in a clinical trial or observational study. Examples include antiviral agents monoclonal antibodies, corticosteroids, vaccines and other pharmacological agents
- Adults (18-64 years)
- Fragile population
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Molnupiravir
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Pregabalin
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Immunomodulator
- Prednisolone
- Vitamin B1
- Vitamin B12
- Vitamin B6
- Adults (18-64 years)
- People at high risk of STIs
- Hospital
- Outpatient clinic
- Monkeypox virus
- Pharmacological intervention
- Vaccination
- Adults (18-64 years)
- People at high risk of STIs
- Men who have sex with men
- Hospital
- Outpatient clinic
- Monkeypox virus
- Pharmacological intervention
- Vaccination
- MVA-BN
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- Non-hospital health centre
- Long-term care facility
- Influenza virus
- Influenza A(H5N1) virus
- Influenza A(H7N9) virus
- Pharmacological intervention
- Vaccination
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Monoclonal antibodies
- AZD3152/Sipavibart
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Adults (18-64 years)
- Fragile population
- People at high risk of STIs
- Immunocompromised host
- PrEP users
- People living with HIV
- Non-hospital health centre
- Telemedicine
- Monkeypox virus
- Pharmacological intervention
- Vaccination
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Monkeypox virus
- Pharmacological intervention
- Antivirals
- Tecovirimat
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Molnupiravir